A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 801–900 of 1,018
Biopharmaceutics Classification System: A Regulatory Approach
Reddy, B. B. K., & Karunakar, A. (2011) · Dissolution Technologies · doi:10.14227/dt180111p31 · Cited by 101
Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals
Araújo, F., das Neves, J., Martins, J. P., Granja, P. L., Santos, H. A., & Sarmento, B. F. C. C. (2017) · Progress in Materials Science · doi:10.1016/j.pmatsci.2017.05.001 · Cited by 86
Albendazole Generics—A Comparative In Vitro Study
Galia, E., Horton, J., & Dressman, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018907527253 · Cited by 80
Lipka, E., & Amidon, G. L. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00022-x · Cited by 81
Self-citationChitosan functionalized poly (ε-caprolactone) nanoparticles for amphotericin B delivery
Marcano, R. G. D. J. V., Tominaga, T. T., Khalil, N. M., Pedroso, L. S., & Mainardes, R. M. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.08.142 · Cited by 79
Challenges and innovations of drug delivery in older age
Khan, M. S., & Roberts, M. S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.003 · Cited by 83
Sayad, B., Sobhani, M., & Khodarahmi, R. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.04.018 · Cited by 80
“The acid dissociation constant (pKa) of sofosbuvir is around 9.3 and as the class 3 compound possess high-solubility and low-permeability (12) .”
InfluentialScreening and Preparation of Cocrystals: A Comparative Study of Mechanochemistry vs Slurry Methods
Haskins, M. M., & Zaworotko, M. J. (2021) · Crystal Growth & Design · doi:10.1021/acs.cgd.1c00418 · Cited by 80
“11 In general, the potential utility of pharmaceutical cocrystals tends to be related to the Biopharmaceutics Classi fi cation System (BCS) 12 class of the API in question.”
Rossier, B., Jordan, O., Allémann, É., & Rodríguez‐Nogales, C. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01559-0 · Cited by 87
“An increasing number of new drug candidates are charac - terized by an extremely low solubility, belonging to class II or class IV of the Biopharmaceutics Classification System (BCS) [ 1, 2].”
BackgroundFabrication of pectin-based nanoemulsions loaded with itraconazole for pharmaceutical application
Burapapadh, K., Kumpugdee-Vollrath, M., Chantasart, D., & Sriamornsak, P. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.04.071 · Cited by 90
Barker, R., Abrahamsson, B., & Kruusmägi, M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24177 · Cited by 84
Silica Nanoparticles To Control the Lipase-Mediated Digestion of Lipid-Based Oral Delivery Systems
Tan, A., Simović, S., Davey, A. K., Rades, T., Boyd, B. J., & Prestidge, C. A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp9002442 · Cited by 79
Application of spray granulation for conversion of a nanosuspension into a dry powder form
Bose, S., Schenck, D., Ghosh, I., Hollywood, A., Maulit, E., & Ruegger, C. E. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.020 · Cited by 79
Encapsulation of Functional Lipophilic Food and Drug Biocomponents
Dima, Ş., Dima, C. V., & Iordăchescu, G. (2015) · Food Engineering Reviews · doi:10.1007/s12393-015-9115-1 · Cited by 85
Foltz, M., Cerstiaens, A., van Meensel, A., Mols, R., van der Pijl, P. C., Duchateau, G. S. M. J. E., & Augustijns, P. (2008) · Peptides · doi:10.1016/j.peptides.2008.03.021 · Cited by 79
“[3] Amidon GL, Lennernas H, Shah VP, Crison JR.”
BackgroundChen, Z., Lu, Y., Du, S., Shang, K.-X., & Cai, C.-B. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.017 · Cited by 79
Recent Advances in Physicochemical and ADMET Profiling in Drug Discovery
Wang, J., & Skolnik, S. M. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900117 · Cited by 79
Absorption Rate Limit Considerations for Oral Phosphate Prodrugs
Heimbach, T., Oh, D.-M., Li, L. Y., Forsberg, M., Savolainen, J., Leppänen, J., Matsunaga, Y., Flynn, G. L., & Fleisher, D. (2003) · Pharmaceutical Research · doi:10.1023/a:1023827017224 · Cited by 79
“, a drug with low solubility and high permeability) (14).”
BackgroundInfluentialKnopp, M. M., Nguyen, J. H., Becker, C., Francke, N. M., Jørgensen, E. B., Holm, P., Holm, R., Mu, H., Rades, T., & Langguth, P. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.02.007 · Cited by 83
Thiry, J., Lebrun, P., Vinassa, C., Adam, M., Netchacovitch, L., Ziémons, E., Hubert, P., Krier, F., & Évrard, B. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.003 · Cited by 79
“These compounds mostly belong to the second class of the biopharmaceutics classification system (BCS) described by Amidon et al. in 1995 (Amidon et al., 1995).”
BackgroundEnright, E. F., Joyce, S. A., Gahan, C. G. M., & Griffin, B. T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01155 · Cited by 81
The Mean Dissolution Time Depends on the Dose/Solubility Ratio
Rinaki, E., Dokoumetzidis, A., & Macheras, P. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1022652004114 · Cited by 79
Saha, P., & Kou, J. H. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00113-2 · Cited by 79
Takeuchi, S., Tsume, Y., Amidon, G. E., & Amidon, G. L. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24112 · Cited by 78
Self-citationIn Silico Assessment of ADME Properties: Advances in Caco-2 Cell Monolayer Permeability Modeling
Pham‐The, H., Cabrera‐Pérez, M. Á., Nam, N., Castillo‐Garit, J. A., Rasulev, B., Le‐Thi‐Thu, H., & Casañola‐Martín, G. M. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181130140350 · Cited by 93
Bermejo, M., Hens, B., Dickens, J., Mudie, D. M., Paixão, P. J. P. A., Tsume, Y., Shedden, K., & Amidon, G. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010074 · Cited by 88
“We hypothesize that the present fluids will impact the amount of drug dissolved, even though the drug has no limited capacity with respect to dissolution (BCS class 1/2a/3) and regardless of favorable pH to initiate dissolution of the drug in the intestine (BCS class 2a) [47].”
BackgroundSelf-citationMarković, M., Zur, M., Ragatsky, I., Cvijić, S., & Dahan, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121175 · Cited by 78
O’Shea, J. P., Augustijns, P., Brandl, M., Brayden, D. J., Brouwers, J., Griffin, B. T., Holm, R., Jacobsen, A.-C., Lennernäs, H., Vinarov, Z., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106098 · Cited by 85
Self-citationNanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications
Ravichandran, R. (2009) · doi:10.1080/19430850903430427 · Cited by 78
“According to the BCS, drug substances are classified as follows [ 46 , 47 ] :”
Manrique, Y. J., Lee, D. J., Islam, F., Nissen, L. M., Cichero, J. A. Y., Stokes, J. R., & Steadman, K. J. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j39w3v · Cited by 78
“The Biopharmaceutical Classification Scheme (BCS) classifies drugs according to two major physicochemical properties, solubility and permeability, that contribute to bioavailability upon oral administration (32).”
BackgroundMethodWillmann, S., Thelen, K., Becker, C., Dressman, J., & Lippert, J. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.06.003 · Cited by 78
An integrated early formulation strategy – From hit evaluation to preclinical candidate profiling
Maas, J., Kamm, W., & Hauck, G. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.09.011 · Cited by 78
Fast disintegrating tablets of nisoldipine for intra-oral administration
Maghraby, G. M. E., & Elsergany, R. N. (2013) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2013.813543 · Cited by 78
Taupitz, T., Dressman, J., & Klein, S. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.11.027 · Cited by 78
Effective polymeric dispersants for vacuum, convection and freeze drying of drug nanosuspensions
Kim, S., & Lee, J. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.010 · Cited by 78
Transdermal iontophoresis revisited
Panchagnula, R., Pillai, O., Nair, V. B., & Ramarao, P. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00111-3 · Cited by 78
Singh, B., & Sharma, N. (2009) · Biomacromolecules · doi:10.1021/bm9004645 · Cited by 78
Kawabata, Y., Yamamoto, K., Debari, K., Onoue, S., & Yamada, S. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.12.009 · Cited by 78
Preparation and Characterization of Solid Dispersions of Piroxicam with Hydrophilic Carriers
Valizadeh, H., Zakeri‐Milani, P., Barzegar-Jalali, M., Mohammadi, G., Danesh-Bahreini, M.-A., Adibkia, K., & Nokhodchi, A. (2006) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040600814965 · Cited by 78
Mechanism of controlled release kinetics from medical devices
Raval, A., Parikh, J. K., & Engineer, C. (2010) · Brazilian Journal of Chemical Engineering · doi:10.1590/s0104-66322010000200001 · Cited by 78
Investigation on the Possibility of Biowaivers for Ibuprofen
Álvarez, C., Núñez, I., Torrado, J. J., Gordon, J., Potthast, H., & García‐Arieta, A. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22472 · Cited by 78
Tran, P., & Park, J. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00516-0 · Cited by 86
A theoretical and spectroscopic study of γ-crystalline and amorphous indometacin
Strachan, C. J., Rades, T., & Gordon, K. C. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.2.0012 · Cited by 77
“It is practically insoluble in water and can be classified as a Class II drug in the Biopharmaceutical Classification System (Amidon et al 1995; US Department of Health and Human Services 2000).”
BackgroundStable carbamazepine colloidal systems using the cosolvent technique
Douroumis, D., & Fahr, A. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.12.003 · Cited by 77
Sievens-Figueroa, L., Pandya, N., Bhakay, A., Keyvan, G., Michniak‐Kohn, B. B., Bilgili, E. A., & Davé, R. N. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9875-3 · Cited by 77
Neirinckx, E., Vervaet, C., Boever, S. D., Remon, J. P., Gommeren, K., Daminet, S., Backer, J. F. A. D., & Croubels, S. (2010) · Research in Veterinary Science · doi:10.1016/j.rvsc.2010.02.002 · Cited by 77
Polymorph Discrimination Using Low Wavenumber Raman Spectroscopy
Roy, S., Chamberlin, B. L., & Matzger, A. J. (2013) · Organic Process Research & Development · doi:10.1021/op400102e · Cited by 77
Improving Ibuprofen solubility by surfactant-facilitated self-assembly into mixed micelles
Stoyanova, K., Vinarov, Z., & Tcholakova, S. S. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2016.10.011 · Cited by 77
“[15], defines the so-called “dose number” (Do), which takes into account both the drug dose per given volume and the equilibrium drug solubility.”
BackgroundDevelopment and applications of a physiologically-based model of paediatric oral drug absorption
Johnson, T. N., Bonner, J. J., Tucker, G. T., Turner, D. B., & Jamei, M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.01.009 · Cited by 77
“The shift in BCS classification of drugs by age and gastric volume has been described previously (Batchelor, 2014a) based on proposed gastric volumes of 25 mL or 121 mL in a 10 year old child compared to the adult value of 250 mL.”
MethodInfluentialEddington, N. D., Marroum, P. J., Uppoor, R. S., Hussain, A., & Augsburger, L. L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011988601696 · Cited by 77
Taub, M. E., Kristensen, L. L., & Frøkjær, S. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00015-5 · Cited by 77
Jejunal permeability and hepatic extraction of fluvastatin in humans
Lindahl, A., Sandström, R., Ungell, A.-L., Abrahamsson, B., Knutson, T. W., Knutson, L., & Lennernäs, H. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90145-9 · Cited by 77
Self-citationNew Solid Forms of the Anti-HIV Drug Etravirine: Salts, Cocrystals, and Solubility
Rajput, L., Sanphui, P., & Desiraju, G. R. (2013) · Crystal Growth & Design · doi:10.1021/cg4007058 · Cited by 76
Ueda, K., & Taylor, L. S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00061 · Cited by 76
An interesting relationship between drug absorption and melting point
Chu, K. A., & Yalkowsky, S. H. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.026 · Cited by 76
Moes, J. J., Koolen, S. L. W., Huitema, A. D. R., Schellens, J. H. M., Beijnen, J. H., & Nuijen, B. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.09.016 · Cited by 76
Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples
Rinaki, E., Dokoumetzidis, A., Valsami, G. N., & Macheras, P. E. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041450.25106.c8 · Cited by 76
“The experience gained with the development (1) and implementation of the biopharmaceutics classification system (BCS) has shown that drug regulatory aspects (2–4) are benefited if are scientifically based.”
BackgroundIn vitro–in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol
Jinno, J.-I., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.013 · Cited by 76
“This can be solved by various formulation techniques [4–16] that improve solubility and/or dissolution of such drugs, especially for Biopharmaceutics Classification System (BCS) Class 2 compounds [17].”
BackgroundLarregieu, C. A., & Benet, L. Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4007858 · Cited by 88
Thelen, K., Coboeken, K., Willmann, S., Dressman, J., & Lippert, J. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22825 · Cited by 80
Hosey, C. M., Chan, R., & Benet, L. Z. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9845-2 · Cited by 86
Ashiru-Oredope, D. A. I., Patel, R., & Basit, A. W. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.10.029 · Cited by 76
Biowaiver Monographs for Immediate Release Solid OralDosage Forms: Prednisolone
Vogt, M., Derendorf, H., Krämer, J., Junginger, H. E., Midha, K. K., Shah, V. P., Stavchansky, S., Dressman, J., & Barends, D. M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20768 · Cited by 78
“The lack of reported in vitro/ in vivo correlations is consistent with that classification.(77)”
ResultSelf-citationFood Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies
Tistaert, C., Heimbach, T., Xia, B., Parrott, N., Samant, T. S., & Kesisoglou, F. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.05.024 · Cited by 75
Sigfridsson, K., Lundqvist, A. J., & Strimfors, M. (2009) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903025855 · Cited by 75
Lozoya-Agulló, I., Zur, M., Wolk, O., Beig, A., González‐Álvarez, I., González‐Álvarez, M., Merino‐Sanjuán, M., Bermejo, M., & Dahan, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.014 · Cited by 77
Highly soluble olanzapinium maleate crystalline salts
Thakuria, R., & Nangia, A. K. (2011) · CrystEngComm · doi:10.1039/c0ce00787k · Cited by 75
Mahmoud, D. B. E. D., Shukr, M. H., & Bendas, E. R. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.09.045 · Cited by 75
Olanzapinium Salts, Isostructural Solvates, and Their Physicochemical Properties
Thakuria, R., & Nangia, A. K. (2013) · Crystal Growth & Design · doi:10.1021/cg400692x · Cited by 75
Berggren, S., Hoogstraate, J. A., Fagerholm, U., & Lennernäs, H. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.12.004 · Cited by 75
Self-citationFormulate-ability of ten compounds with different physicochemical profiles in SMEDDS
Thi, T. D., Speybroeck, M. V., Barillaro, V., Martens, J. A., Annaert, P., Augustijns, P., Humbeeck, J. V., Vermant, J., & den Mooter, G. V. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.09.012 · Cited by 82
A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions
Shah, D. A., Murdande, S. B., & Dave, R. H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24694 · Cited by 80
Active intestinal drug absorption and the solubility-permeability interplay
Porat, D., & Dahan, A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.058 · Cited by 78
Current development in the formulations of non-injection administration of paclitaxel
Du, X., Khan, A. R., Fu, M., Ji, J., Yu, A., & Zhai, G. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.03.030 · Cited by 79
Tannergren, C., Knutson, T., Knutson, L., & Lennernäs, H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01722.x · Cited by 74
Self-citationTheoretical Predictions of Drug Absorption in Drug Discovery and Development
Stenberg, P., m, C. A. S. B., Luthman, K., & Artursson, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00005 · Cited by 81
Parr, A. F., Hidalgo, I. J., Bode, C., Brown, W. E., Yazdanian, M. A., Ángel-González, M., Sagawa, K., Miller, K., Jiang, W., & Stippler, E. S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1773-4 · Cited by 74
The composite solubility versus pH profile and its role in intestinal absorption prediction
Hendriksen, B. A., Felix, M. V. S., & Bolger, M. B. (2003) · AAPS PharmSci · doi:10.1208/ps050104 · Cited by 74
“In general, the rate of change of dissolved drug concentration in a luminal GIT compartment depends on 6 different processes: (1) transit of drug into a compartment, (2) transit of drug out of a compartment, (3) release of drug from the formulation in the compartment, (4) dissolution of the drug particles, (5) luminal…”
BackgroundBikiaris, D. Ν. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.618182 · Cited by 74
“To improve the solubility and dissolution rate of these drugs several technological methods have been reported such as: i) reducing particle size to increase surface area, ii) solubilization in surfactant systems, iii) formation of water-soluble complexes, iv) use of prodrug and drug derivatization approaches, such as…”
MethodIn Vitro Absorption Studies and Their Relevance to Absorption from the GI Tract
Ungell, A.-L. B. (1997) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049709148694 · Cited by 82
Khan, M. Z. I., Raušl, D., Zanoški, R., Zidar, S., Mikulčić, J. H., Krizmanić, L., Eškinja, M., Mildner, B., & Knežević, Z. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.1630 · Cited by 74
Purely in Silico BCS Classification: Science Based Quality Standards for the World’s Drugs
Dahan, A., Wolk, O., Kim, Y. H., Ramachandran, C., Crippen, G. M., Takagi, T., Bermejo, M., & Amidon, G. L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400485k · Cited by 78
Self-citationSrivastava, A. K., Wadhwa, S., Ridhurkar, D., & Mishra, B. (2005) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-200054313 · Cited by 74
The use of spray-drying to enhance celecoxib solubility
Fouad, E. A., El‐Badry, M., Mahrous, G. M., Alanazi, F. K., Neau, S. H., & Alsarra, I. A. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.587428 · Cited by 74
German, P., Mathias, A. A., Brainard, D. M., & Kearney, B. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0397-0 · Cited by 74
“3], and high apparent permeability, and as such is a Biopharmaceutics Classification System Class II compound [11].”
BackgroundVelaga, S. P., Djuriš, J., Cvijić, S., Rozou, S., Russo, P., Colombo, G., & Rossi, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.09.002 · Cited by 74
“D0 in the respiratory zone can be calculated using the standard BCS equation (Amidon et al., 1995):”
BackgroundMethodInfluentialMitchell, S. A., Reynolds, T. D., & Dasbach, T. P. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00293-4 · Cited by 74
Eid, R. K., Ashour, D. S., Essa, E. A., Maghraby, G. M. E., & Arafa, M. F. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115826 · Cited by 78
RetractedMolecular Dynamics Simulations of the Interaction of Beta Cyclodextrin with a Lipid Bilayer
Khuntawee, W., Wolschann, P., Rungrotmongkol, T., Wong-ekkabut, J., & Hannongbua, S. V. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00152 · Cited by 73
Gastrointestinal Drug Absorption: Is It Time to Consider Heterogeneity as Well as Homogeneity?
Macheras, P. E., & Argyrakis, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012183313218 · Cited by 74
Miller, J. M., & Dahan, A. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.017 · Cited by 76
“…the apparent aqueous solubility of the co-administered lipophilic drug, it is quite rare to consider their effect on the apparent permeability, the most important parameter (together with the solubility) dictating oral absorption (Amidon et al., 1995; Dahan et al., 2009, 2010a; Lennernas, 1998).”
BackgroundTurbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals
Crisp, M. T., Tucker, C. J., Rogers, T. L., Williams, R. O., & Johnston, K. P. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.11.011 · Cited by 73
Modern Prodrug Design for Targeted Oral Drug Delivery
Dahan, A., Zimmermann, E. M., & Ben‐Shabat, S. (2014) · Molecules · doi:10.3390/molecules191016489 · Cited by 73
“Since intestinal permeability is, alongside the drug solubility, the most important factors dictating drug absorption following oral administration [88–93], the improved permeability achieved by this approach may enhance “developability” and drug-like properties [94–96], thus allowing new oral treatment options.”
BackgroundWyttenbach, N., Janas, C., Siam, M., Lauer, M. E., Jacob, L. I., Scheubel, E., & Page, S. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.01.009 · Cited by 73
Lai, F., Pini, E., Corrias, F., Perricci, J., Manconi, M., Fadda, A. M., & Sinico, C. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.03.047 · Cited by 73
Current Perspectives of Solubilization: Potential for Improved Bioavailability
Mallick, S., Pattnaik, S., Swain, K., & De, P. K. (2007) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040701429333 · Cited by 79
Khan, J., Rades, T., & Boyd, B. J. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1829-5 · Cited by 76
Kalivoda, A., Fischbach, M., & Kleinebudde, P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.009 · Cited by 73
Permeability classification of representative fluoroquinolones by a cell culture method
Volpe, D. A. (2004) · AAPS PharmSci · doi:10.1208/ps060213 · Cited by 73
Eco-friendly nanocellulose and its biomedical applications: current status and future prospect
Nehra, P., & Chauhan, R. P. (2020) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2020.1817706 · Cited by 74
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.